MarketCap
Facebook
X
Telegram
Aethlon Medical Balance Sheet 2026-2010 | AEMD
Brief balance sheet overview of Aethlon Medical
Balance sheet changes are traced across five available annual reports between 2022 and 2026.
Assets finished at $6.3 million versus $19.4 million initially, losing -67.4%. The balance sheet contracted.
Liabilities expanded faster than the asset base, -40.4% versus -67.4%. Debt-service capacity deserves attention.
Equity funds 77.2% of assets versus 87.5% initially. This creates a conservative balance sheet structure.
Cash equals 79.4% of the balance sheet, compared with 87.9% five periods ago. This is the readily available cushion.
The accumulated result is -$175.1 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
What the balance sheet shows
Aethlon Medical's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.
Annual Balance Sheet Aethlon Medical
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -4.85 M | -4.5 M | -13.3 M | -16.3 M | - | -9.46 M | -2.87 M | -6.13 M | -1.04 M | -1.6 M | -700 K | 1.28 M | 2.56 M | 3.52 M | 2.36 M | - |
Long Term Debt |
- | 337 K | 650 K | 940 K | 603 K | - | - | - | 841 K | 519 K | 528 K | 155 K | 776 K | - | - | - | - |
Long Term Debt Current |
337 K | 313 K | 291 K | 269 K | 127 K | 42.5 K | 98.6 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 42.5 K | - | 841 K | 519 K | 528 K | 155 K | 776 K | - | - | - | - |
Total Current Liabilities |
1.45 M | 1.9 M | 1.83 M | 1.51 M | 1.82 M | 1.38 M | 1.07 M | 1.82 M | 478 K | 612 K | 527 K | 574 K | 15.6 M | 9.64 M | 10.1 M | - | - |
Total Liabilities |
1.45 M | 2.24 M | 2.48 M | 2.44 M | 2.43 M | 1.38 M | 1.11 M | 1.82 M | 1.32 M | 1.13 M | 1.05 M | 729 K | 16.4 M | 9.64 M | 10.1 M | 6.54 M | - |
Deferred Revenue |
- | - | - | - | 345 K | 115 K | 100 K | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-175 M | -168 M | -155 M | -142 M | -130 M | -120 M | -112 M | -106 M | -99.5 M | -93.8 M | -86.5 M | -81.6 M | -74.8 M | -61.5 M | -56.6 M | -48.5 M | - |
Total Assets |
6.33 M | 7.36 M | 8.25 M | 17.5 M | 19.4 M | 10.7 M | 10.4 M | 4.12 M | 7.35 M | 1.73 M | 2.56 M | 1.38 M | 1.7 M | 497 K | 839 K | 567 K | - |
Cash and Cash Equivalents |
5.03 M | 5.5 M | 5.44 M | 14.5 M | 17.1 M | 9.86 M | 9.6 M | 3.83 M | 6.97 M | 1.56 M | 2.12 M | 856 K | 1.25 M | 125 K | 144 K | 15.7 K | 68 K |
Book Value |
4.89 M | 5.12 M | 5.77 M | 15.1 M | 17 M | 9.29 M | 9.28 M | 2.3 M | 6.03 M | 595 K | 1.5 M | 651 K | -14.7 M | -9.14 M | -9.3 M | -5.98 M | - |
Total Shareholders Equity |
4.89 M | 5.12 M | 5.77 M | 15.1 M | 17 M | 9.43 M | 9.41 M | 2.43 M | 6.13 M | 676 K | 1.55 M | 615 K | -14.9 M | -9.14 M | -9.3 M | -5.98 M | -4.4 M |
All numbers in USD currency
Quarterly Balance Sheet Aethlon Medical
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
86.9 K | 172 K | 255 K | 86.9 K | 172 K | 255 K | 337 K | 418 K | 497 K | 574 K | 650 K | 725 K | 798 K | 870 K | 940 K | 1.01 M | 1.08 M | 567 K | 603 K | 287 K | - | - | - | - | - | 16.8 K | 42.5 K | 67.7 K | 92.6 K | 117 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 155 K | 264 K | 991 K | 1 M | 776 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.34 M | 1.58 M | 1.88 M | 1.34 M | 1.58 M | 1.88 M | 2.24 M | 2.19 M | 2.83 M | 2.7 M | 2.48 M | 2.83 M | 2.51 M | 2.69 M | 2.44 M | 3.45 M | 3.18 M | 2.21 M | 2.43 M | 1.36 M | 1.38 M | - | 1.38 M | 1.24 M | 1.49 M | 1.24 M | 1.11 M | 878 K | 1.26 M | 1.91 M | 1.82 M | 1.78 M | 1.26 M | 1.34 M | 1.32 M | 1.15 M | 1.13 M | 1.46 M | 1.13 M | 789 K | 1.08 M | 1.09 M | 1.03 M | 884 K | 829 K | 897 K | 729 K | 1.86 M | 4.38 M | 4.67 M | 16.4 M | - | - | - | 9.64 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 574 K | 574 K | 459 K | 345 K | 230 K | 115 K | 115 K | 115 K | - | 507 K | 307 K | 100 K | 100 K | 100 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-173 M | -171 M | -170 M | -173 M | -171 M | -170 M | -168 M | -162 M | -160 M | -157 M | -155 M | -152 M | -149 M | -146 M | -142 M | -140 M | -137 M | -133 M | -130 M | -127 M | -124 M | -122 M | -120 M | -118 M | -115 M | -113 M | -112 M | -110 M | -109 M | -108 M | -106 M | -104 M | -102 M | -101 M | -99.5 M | -98.1 M | -96.9 M | -95.6 M | -93.8 M | -92.1 M | -90.9 M | -88.6 M | -86.5 M | -85.3 M | -84 M | -82.8 M | -81.6 M | -80.7 M | -79.3 M | -78.5 M | -74.8 M | -67.2 M | -65.1 M | -61.8 M | -61.5 M | -58.7 M | -59 M | -57.6 M | -56.6 M | - | - | - | - |
Total Assets |
8.06 M | 7.32 M | 5.31 M | 8.06 M | 7.32 M | 5.31 M | 7.36 M | 6.53 M | 8.85 M | 11.4 M | 8.25 M | 10.4 M | 12.8 M | 15.8 M | 17.5 M | 20.7 M | 23 M | 17.1 M | 19.4 M | 21.9 M | 23.9 M | 25.9 M | 10.7 M | 12.7 M | 12.7 M | 15.1 M | 16.4 M | 4.68 M | 4.68 M | 1.28 M | 2.93 M | 4.95 M | 4.95 M | 5.27 M | 7.35 M | 5.75 M | 1.15 M | 509 K | 1.73 M | 790 K | 951 K | 1.46 M | 2.53 M | 3.59 M | 4.71 M | 5.97 M | 1.38 M | 3.16 M | 1.09 M | 1.14 M | 1.7 M | 2.11 M | 411 K | 195 K | 497 K | 307 K | 475 K | 823 K | 839 K | 903 K | 323 K | 322 K | 567 K |
Cash and Cash Equivalents |
6.96 M | 5.85 M | 3.77 M | 6.96 M | 5.85 M | 3.77 M | 5.5 M | 4.83 M | 6.86 M | 9.07 M | 5.44 M | 7.97 M | 10.2 M | 12.9 M | 14.5 M | 17.5 M | 19.6 M | 14.9 M | 17.1 M | 20.4 M | 23.2 M | 25.2 M | 9.91 M | 12.1 M | 4.06 M | 14.5 M | 9.6 M | 4.06 M | 4.06 M | 786 K | 2.49 M | 4.82 M | 4.82 M | 5.08 M | 6.97 M | 5.61 M | 920 K | 327 K | 1.56 M | 629 K | 556 K | 1.29 M | 2.12 M | 3.25 M | 4.21 M | 5.65 M | 856 K | 2.78 M | 526 K | 807 K | 1.25 M | 1.85 M | 8.75 K | 31.7 K | 125 K | 108 K | 272 K | 596 K | 144 K | 355 K | 45.6 K | 13.4 K | 15.7 K |
Book Value |
6.71 M | 5.75 M | 3.42 M | 6.71 M | 5.75 M | 3.42 M | 5.12 M | 4.33 M | 6.02 M | 8.71 M | 5.77 M | 7.61 M | 10.3 M | 13.1 M | 15.1 M | 17.3 M | 19.9 M | 14.9 M | 17 M | 20.6 M | 22.5 M | 25.9 M | 9.29 M | 11.4 M | 11.2 M | 13.8 M | 15.3 M | 3.8 M | 3.42 M | -633 K | 1.11 M | 3.17 M | 3.69 M | 3.93 M | 6.03 M | 4.6 M | 19.5 K | -950 K | 595 K | 1.08 K | -133 K | 375 K | 1.5 M | 2.71 M | 3.88 M | 5.08 M | 651 K | 1.29 M | -3.29 M | -3.52 M | -14.7 M | 2.11 M | 411 K | 195 K | -9.14 M | 307 K | 475 K | 823 K | 839 K | 903 K | 323 K | 322 K | 567 K |
Total Shareholders Equity |
6.71 M | 5.75 M | 3.42 M | 6.71 M | 5.75 M | 3.42 M | 5.12 M | 4.33 M | 6.02 M | 8.71 M | 5.77 M | 7.61 M | 10.3 M | 13.1 M | 15.1 M | 17.3 M | 19.9 M | 14.9 M | 17.1 M | 20.6 M | 22.9 M | 24.7 M | 9.29 M | 11.6 M | 13.7 M | 15.3 M | 9.41 M | 3.93 M | 149 K | 1.15 M | 2.43 M | 3.29 M | 4.13 M | 5.22 M | 6.13 M | 4.7 M | 109 K | -865 K | 676 K | 74.5 K | -67.6 K | 433 K | 1.55 M | 2.75 M | 3.9 M | 5.08 M | 615 K | 1.22 M | -3.42 M | -3.69 M | -14.9 M | -10.8 M | -11.5 M | -8.82 M | -9.14 M | -7.32 M | -8.47 M | -8.39 M | -9.3 M | -6.11 M | -6.34 M | -6.71 M | -5.98 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Aethlon Medical, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
France
China
Canada
Australia
Britain
Israel
